◆ Inside the Latest Quarter (April-June 2026)

Synektik (SNT) — the variant view

Synektik's record quarter came from robot deliveries; the backlog behind it is less than a sixth of the quarter's sales.

📈 SNT valuation, revenue & earnings — P/E, P/S, revenue, EPS →

Synektik's April-June 2026 quarter, the third of its fiscal year, was the largest in its history. Revenue was 292,3 million złoty against 154,2 million złoty a year earlier, operating profit 66,1 million złoty against 36,4 million złoty, and continuing net profit 55,1 million złoty against 30,5 million złoty, 6,46 złoty a share1.

Apr-Jun 2026 against 2025 (zł m)Revenue292,3 (154,2)Equipment sales175,3 (57,4)Recurring103,6 (82,2)Continuing profit55,1 (30,5)Radiopharma EBITDA3,6 (5,2)Prior-year quarter in brackets; Synektik interim report, August 2026
Everything up except the tracers.

Robots drove it. Equipment sales in the equipment segment were 175,3 million złoty, up 206%, and the segment's external revenue doubled to 278,9 million złoty2. Ten da Vinci systems were sold in the quarter and 28 in nine months3. Recurring revenue, the instruments and service, grew 26% to 103,6 million złoty4. Segment EBITDA rose 78% to 76,1 million złoty, a margin of 27,3%5. Polish da Vinci procedures rose 35% to 6,9 thousand, Czech and Slovak 18% to 4,0 thousand6.

The small business went the other way. Radiopharmaceutical revenue fell to 13,4 million złoty from 14,8 million złoty, and EBITDA to 3,6 million złoty from nearly 5,2 million złoty, on lower complementary sales and higher logistics costs7.

Cash improved: operating cash flow was 63,3 million złoty against minus 5,0 million złoty8. The order book did not grow as fast as sales: orders in the quarter were 112,0 million złoty against 99,0 million złoty, and the backlog at quarter end 44,2 million złoty9.

Over nine months the picture is the same. Revenue was 733,4 million złoty against 482,1 million złoty, continuing EBITDA 189,6 million złoty against 122,5 million złoty, and continuing earnings 16,17 złoty a share against 10,05 złoty10. Reported net profit of 386,4 million złoty includes the 261,3 million złoty demerger gain11.

After the quarter Synektik signed its first Estonian contract12, and in June the chairman of the supervisory board's holding company sold its entire 16,13% stake13. The company does not publish guidance14. The number for the next quarter is the backlog: a quarter of 292 million złoty was built on deliveries that the 44,2 million złoty backlog cannot repeat.

References
  1. ReportedRevenue was 292,3 million złoty against 154,2 million złoty a year earlier, operating profit 66,1 million złoty against 36,4 million złoty, and continuing net profit 55,1 million złoty against 30,5 million złoty, 6,46 złoty a share.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  2. ReportedEquipment sales in the equipment segment were 175,3 million złoty, up 206%, and the segment's external revenue doubled to 278,9 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  3. ReportedTen da Vinci systems were sold in the quarter and 28 in nine months.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  4. ReportedRecurring revenue, the instruments and service, grew 26% to 103,6 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  5. ReportedSegment EBITDA rose 78% to 76,1 million złoty, a margin of 27,3%.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  6. ReportedPolish da Vinci procedures rose 35% to 6,9 thousand, Czech and Slovak 18% to 4,0 thousand.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  7. ReportedRadiopharmaceutical revenue fell to 13,4 million złoty from 14,8 million złoty, and EBITDA to 3,6 million złoty from nearly 5,2 million złoty, on lower complementary sales and higher logistics costs.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - radiopharmaceutical segment: plants, products, sales by type and quarterly results. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  8. ReportedCash improved: operating cash flow was 63,3 million złoty against minus 5,0 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  9. ReportedThe order book did not grow as fast as sales: orders in the quarter were 112,0 million złoty against 99,0 million złoty, and the backlog at quarter end 44,2 million złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  10. ReportedRevenue was 733,4 million złoty against 482,1 million złoty, continuing EBITDA 189,6 million złoty against 122,5 million złoty, and continuing earnings 16,17 złoty a share against 10,05 złoty.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  11. ReportedReported net profit of 386,4 million złoty includes the 261,3 million złoty demerger gain.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - the demerger of Syn2bio, shareholders and group structure. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  12. ReportedAfter the quarter Synektik signed its first Estonian contract, and in June the chairman of the supervisory board's holding company sold its entire 16,13% stake.
    Synektik press release, 17 September 2026: 'Synektik signs first contract in Estonia. Another step in the Baltic states expansion' - EUR 9,4 million including nine years of maintenance and ten years of consumables; 142 systems (100 in Poland, 42 in Czechia and Slovakia); the Ukraine plan; targets for foreign and recurring revenue. — September 2026 · publ. 17 September 2026 · source ↗
  13. ReportedAfter the quarter Synektik signed its first Estonian contract, and in June the chairman of the supervisory board's holding company sold its entire 16,13% stake.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  14. ReportedThe company does not publish guidance.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - income statement, segment note, cash flow and balance sheet. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
Sources
Generated September 24, 2026